# Is Sermorelin Legal? FDA Status and Regulations Explained (2026)
**Key Takeaways**
- Sermorelin is an FDA-approved growth hormone releasing hormone (GHRH) analog — one of the few peptides in the therapeutic space with a genuine approval history.
- It's classified as a **Category 1 bulk drug substance**, which means licensed 503A and 503B compounding pharmacies can legally prepare it for patients with a valid prescription.
- Sermorelin is **not a controlled substance** under the DEA's Controlled Substances Act, so it doesn't carry the scheduling restrictions that apply to anabolic steroids or growth hormone itself.
- You **cannot legally buy it without a prescription** — not online, not from a "research chemical" supplier, not from overseas. The Category 1 compounding status applies only within a licensed pharmacy/prescriber relationship.
- The FDA has taken enforcement action against companies marketing unapproved peptide products, including GHRH-class compounds. Consult FDA.gov for current enforcement activity.
- If you're considering Sermorelin therapy, the legal path is straightforward: a licensed provider, a valid prescription, and a licensed compounding pharmacy. Anything outside that chain carries real legal risk.
---
## Regulatory Status at a Glance
| Category | Status | Detail |
|---|---|---|
| **FDA Approval** | Approved (historical) | Originally approved as Geref (sermorelin acetate) for growth hormone deficiency in children; the branded product has since been discontinued |
| **Compounding Category** | Category 1 — Compoundable | Eligible for compounding by licensed 503A and 503B pharmacies |
| **DEA Scheduling** | Not Scheduled | Sermorelin is not a controlled substance under the Controlled Substances Act |
| **Prescription Requirement** | Prescription Required | Cannot be dispensed legally without a valid prescription from a licensed provider |
| **Research Use Only** | Not a legal loophole | "RUO" labeling does not permit human administration; selling for human use under RUO designation violates federal law |
| **International Status** | Varies by jurisdiction | Not widely approved for clinical use outside the US; see International Status section below |
---
## Current FDA Status
Sermorelin's regulatory history is more interesting than most peptides you'll read about, and understanding it matters if you're trying to figure out whether your clinic is operating legally.
Sermorelin acetate — a 29-amino acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH) — was originally FDA-approved under the brand name **Geref**, manufactured by Serono Laboratories.<sup>[1]</sup> The approved indication was diagnostic testing for growth hormone deficiency in children, and later for treatment of idiopathic growth hormone deficiency in prepubertal pediatric patients.<sup>[1]</sup> That approval gave sermorelin a legitimate regulatory foundation that many peptides simply don't have.
The branded Geref product was voluntarily withdrawn from the US market by the manufacturer — not because of safety concerns, but for commercial reasons.<sup>[2]</sup> This is a critical distinction. A drug that's withdrawn for safety reasons gets a very different regulatory treatment than one withdrawn because it wasn't profitable enough. Sermorelin's withdrawal was the latter, which is one reason the FDA has been willing to permit compounding.
Because Sermorelin has an approval history and an established safety record from human clinical use, the FDA placed it on the **Category 1 bulk drug substance list** for compounding.<sup>[3]</sup> Category 1 means the substance has been evaluated and found appropriate for compounding — it's not a blanket approval for any use, but it does mean licensed pharmacies can legally prepare it for patients with a valid medical need and a valid prescription.
What this means practically: your doctor can prescribe compounded sermorelin, a licensed 503A pharmacy can prepare it, and you can legally receive and use it. That's a cleaner legal picture than you get with most peptides.
---
## Compounding Status
The distinction between 503A and 503B compounding matters here, so let's be direct about it.
**503A pharmacies** are traditional compounding pharmacies that prepare medications for individual patients based on a specific prescription.<sup>[4]</sup> Under 503A, a pharmacy can compound sermorelin for a named patient with a valid prescription from a licensed practitioner. These pharmacies are primarily regulated by state pharmacy boards, though they must also comply with FDA requirements — including the prohibition on compounding copies of commercially available drugs (which doesn't apply here, since Geref is no longer commercially available).
**503B outsourcing facilities** are larger-scale compounders that can produce medications in bulk without patient-specific prescriptions, primarily supplying hospitals and clinics.<sup>[4]</sup> They're subject to more stringent FDA oversight, including current Good Manufacturing Practice (cGMP) requirements. Sermorelin's Category 1 status allows it to be compounded under both pathways.
Because Sermorelin is Category 1, there's no FDA prohibition on compounding it — but that doesn't mean anything goes. Compounded sermorelin must still:
- Be prepared by a **licensed 503A or 503B facility** in compliance with USP standards
- Be dispensed only pursuant to a **valid prescription** for a specific patient (503A) or sold to licensed practitioners and healthcare facilities (503B)
- Meet **sterility and potency standards** — sermorelin is administered via subcutaneous injection, so sterility is non-negotiable
- Not be marketed with **disease treatment claims** that would require FDA approval
The typical compounded sermorelin preparation is a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water for subcutaneous injection, usually at concentrations of 2 mg/mL to 9 mg/mL depending on the prescribing protocol.<sup>[5]</sup>
One thing worth knowing: the FDA periodically reviews and updates the bulk drug substance lists. Category 1 status today doesn't guarantee it forever. Providers and pharmacies operating in this space watch the Federal Register for proposed changes. As of March 2026, sermorelin remains Category 1 compoundable.
---
## Enforcement Actions
The FDA and FTC have been increasingly active in the peptide and growth hormone-adjacent space, and it's worth understanding the enforcement pattern even without getting into specific cases.
The FDA's primary enforcement tools in this space are **warning letters** to companies making unapproved drug claims, **import alerts** targeting shipments of unapproved peptide products, and referrals to the Department of Justice for criminal prosecution in egregious cases. The FTC has pursued companies making unsubstantiated health claims about peptides marketed to consumers.
For sermorelin specifically: because it has a legitimate compounding pathway, the enforcement focus tends to fall on companies operating *outside* that pathway — selling sermorelin without a prescription framework, marketing it as a supplement, labeling it "research use only" while clearly targeting human use, or operating as unregistered compounders.
The FDA has taken enforcement action against companies marketing unapproved peptide products, including GHRH-class compounds. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity.<sup>[6]</sup>
If you're buying sermorelin from a website that doesn't require a prescription, doesn't involve a licensed pharmacy, and ships it in unlabeled vials or with "not for human use" disclaimers — that's exactly the profile of operations that draw enforcement attention. The legal risk falls on the seller primarily, but buyers aren't immune, particularly for larger quantities.
---
## Prescription vs. Over-the-Counter vs. Research Use
Let's be straightforward about the three ways people try to access sermorelin and what the law actually says about each.
**Prescription (Legal):** A licensed physician, NP, or PA with prescribing authority evaluates you, determines there's a legitimate medical indication, and writes a prescription for compounded sermorelin. A licensed 503A pharmacy fills it. You inject it subcutaneously, typically in the evening to align with the body's natural GH pulsatility.<sup>[5]</sup> This is the only fully legal pathway for human use in the United States.
**Over-the-Counter (Illegal for human use):** Sermorelin is not available OTC. It's not a supplement. It's not a nutraceutical. Any website selling it without a prescription is operating outside federal law, regardless of how they've labeled the product.
**Research Use Only (Not a loophole):** The "research use only" or "RUO" designation is a real regulatory category — but it applies to laboratory reagents and in-vitro research, not to compounds intended for human administration.<sup>[7]</sup> When a company sells sermorelin labeled "RUO" or "not for human use" to individual consumers who are clearly going to inject it, the FDA doesn't treat that label as a legal shield. The intended use determines the regulatory category, not the label. Selling a drug intended for human use under an RUO label is misbranding under the Federal Food, Drug, and Cosmetic Act.<sup>[7]</sup>
**International Purchasing:** Ordering sermorelin from overseas pharmacies or research suppliers and importing it into the US sits in genuinely murky legal territory. Personal importation of unapproved drugs is technically illegal under federal law, though the FDA has a longstanding informal policy of exercising enforcement discretion for small quantities of drugs for personal use that aren't available domestically.<sup>[8]</sup> Given that sermorelin *is* available through domestic compounding pharmacies, that discretion argument is weaker here than it is for, say, a drug that has no US equivalent. Customs seizures are a real possibility, and the legal exposure increases significantly for larger quantities.
---
## What "Off-Label" Actually Means
This distinction matters, and a lot of providers get it wrong — or deliberately blur it.
Off-label prescribing is a well-established, legal practice in the US. When a drug is FDA-approved for Indication A, a physician can legally prescribe it for Indication B based on clinical judgment and available evidence. Roughly 20% of all prescriptions written in the US are off-label.<sup>[9]</sup>
But here's the catch: off-label prescribing only applies to **FDA-approved drugs**. Sermorelin's branded product (Geref) was approved, then withdrawn. The compounded version of sermorelin isn't an FDA-approved drug — it's a compounded preparation made under the 503A/503B framework. Prescribing compounded sermorelin for adult anti-aging, body composition, or sleep improvement isn't "off-label prescribing" in the technical sense. It's prescribing a compounded preparation for an indication that hasn't been reviewed or approved by the FDA.
That's not necessarily illegal — the compounding framework permits this — but it does carry different liability implications for providers. A physician prescribing compounded sermorelin for adult GH optimization should have:
- A documented clinical rationale in the patient chart
- Informed consent that covers the compounded (not FDA-approved) nature of the product
- A legitimate prescriber-patient relationship, not a five-minute telemedicine questionnaire
- Knowledge of the patient's baseline hormone levels, typically including IGF-1 measurements<sup>[5]</sup>
Providers who skip these steps aren't just taking on malpractice risk — they're operating in ways that attract regulatory scrutiny from state medical boards and the FDA.
---
## State-Level Variations
Federal law sets the floor for sermorelin regulation, but states can — and do — add their own requirements.
**State pharmacy boards** oversee 503A compounding pharmacies and can impose requirements beyond federal minimums. Some state boards have issued specific guidance on peptide compounding; others apply general compounding rules. Before you fill a sermorelin prescription, it's worth confirming that the compounding pharmacy is licensed in your state or ships legally to your state under reciprocal licensing arrangements.
**State medical boards** regulate prescribing practices. A handful of states have issued guidance or taken disciplinary action against providers prescribing peptides without adequate clinical justification. Texas, Florida, and California have all seen increased medical board scrutiny of anti-aging and hormone optimization clinics in recent years, though specific enforcement varies considerably by state.
**Telemedicine rules** affect access significantly. The DEA's telemedicine prescribing rules — which tightened considerably after the COVID-era emergency policies expired — don't directly apply to sermorelin (it's not a controlled substance), but state telemedicine laws may require an in-person visit before certain prescriptions can be issued. If your clinic is operating entirely online and never asks you to come in for labs or a physical exam, that's worth asking about directly.
**Anti-aging clinic regulations** vary. Some states have specific regulations governing hormone optimization clinics; others treat them as standard medical practices. Your state medical board's website is the right place to check current guidance.
---
## International Status
Sermorelin's legal status outside the US is considerably more restrictive in most jurisdictions.
**European Union / EMA:** Sermorelin is not approved by the European Medicines Agency for any current indication. The EU's compounding framework is more restrictive than the US 503A/503B system, and access through licensed compounding is limited in most member states.
**United Kingdom / MHRA:** Sermorelin does not hold a current marketing authorization from the Medicines and Healthcare products Regulatory Agency. It may be available through "specials" — unlicensed medicines prepared for individual patients — but this is subject to strict prescriber justification requirements.
**Australia / TGA:** The Therapeutic Goods Administration has not approved sermorelin for therapeutic use in Australia. The TGA has been particularly active in restricting peptide access, and several GHRH analogs are specifically prohibited from compounding under Australian regulations. Sermorelin's status in Australia is significantly more restricted than in the US.
**Canada / Health Canada:** Sermorelin is not currently approved by Health Canada. It may be accessible through the Special Access Program (SAP) for patients with demonstrated medical need, but this is not a routine pathway for most patients.
The practical implication: if you're a US patient traveling internationally, you may have difficulty legally carrying compounded sermorelin across borders. And if you're considering sourcing sermorelin from international suppliers, you're dealing with a product that may not meet US sterility and potency standards, and you're importing it without a legal pathway.
---
## What This Means for Patients
If you're considering sermorelin therapy, here's how to make sure you're doing it legally.
**Verify the clinic's legitimacy.** A legal sermorelin provider will be a licensed medical practice with a physician, NP, or PA who holds prescribing authority in your state. They'll order baseline labs — at minimum, an IGF-1 level — before prescribing. They'll document a clinical rationale. If a clinic skips labs entirely and prescribes based on a questionnaire alone, that's a red flag.
**Verify the pharmacy.** Your sermorelin should come from a pharmacy that's licensed as a 503A or 503B facility and registered with your state pharmacy board. The National Association of Boards of Pharmacy (NABP) maintains a database of accredited compounding pharmacies at nabp.pharmacy. If your sermorelin is arriving in an unlabeled vial with no pharmacy information, no lot number, and no expiration date — that's not from a licensed compounder.
**Red flags for illegal operations:**
- No prescription required
- "Research use only" or "not for human use" labeling
- Prices dramatically below market (licensed compounding has real costs)
- No licensed pharmacy name or contact information on the label
- Shipped from overseas with no customs declaration
- Provider who can't or won't explain the compounding pharmacy they use
**If you're offered an illegal peptide:** Don't purchase it. The legal risk to buyers is real, particularly for repeated purchases or larger quantities. And the safety risk is arguably bigger — unregulated peptide products have no sterility guarantee, no verified potency, and no accountability chain if something goes wrong.
**To report suspicious sellers:** The FDA's MedWatch program (fda.gov/safety/medwatch) accepts reports of suspected illegal drug sales. The FTC accepts reports at reportfraud.ftc.gov.
---
## Legal Alternatives
If you're looking at sermorelin for growth hormone optimization and want to understand the full legal landscape of your options, here are the relevant alternatives.
[Ipamorelin](/peptides/ipamorelin) is a growth hormone secretagogue (GHS) that works through a different receptor pathway (ghrelin receptor) but produces similar downstream effects on GH pulsatility. It's also Category 1 compoundable and frequently prescribed alongside sermorelin in combination protocols.
[CJC-1295](/peptides/cjc-1295) is another GHRH analog often combined with ipamorelin. Its compounding status has been more contested than sermorelin's, so confirm current status with your provider.
[Tesamorelin](/peptides/tesamorelin) is an FDA-approved GHRH analog (brand name Egrifta) indicated specifically for HIV-associated lipodystrophy. It has a stronger regulatory standing than compounded sermorelin for that specific indication.
For patients with documented adult growth hormone deficiency, **recombinant human growth hormone (rhGH)** products — including Norditropin, Genotropin, and Humatrope — are FDA-approved and available by prescription. These are controlled more strictly than sermorelin (GH itself is a Schedule III-adjacent substance under the Anabolic Steroid Control Act framework for specific misuse contexts), but they're the gold standard for confirmed GHD.
For the broader anti-aging and body composition context, [peptide therapy clinics](/clinics) that operate legally will walk you through the full menu of compoundable options and help you understand which has the best evidence base for your specific goals.
---
## What the Evidence Does Not Show
**Pending FDA decisions:** The FDA's bulk drug substance lists are subject to ongoing review. While sermorelin is currently Category 1, the FDA can propose changes, accept public comment, and revise categories. Providers and patients should monitor the Federal Register for any proposed rulemaking affecting GHRH analogs.
**Adult GH deficiency indication:** Sermorelin's original FDA approval was for pediatric growth hormone deficiency. There is no FDA-approved indication for adult use — not for anti-aging, not for body composition, not for sleep optimization. The clinical evidence for adult use exists (primarily from studies using IGF-1 as a surrogate endpoint), but it hasn't been reviewed or approved by the FDA in this context.<sup>[5]</sup>
**Long-term safety data in adults:** Most clinical data on sermorelin comes from pediatric studies or short-duration adult studies. Long-term safety data for multi-year adult use at the doses commonly prescribed in anti-aging contexts — typically 100–500 mcg per day administered subcutaneously — is limited.<sup>[5]</sup>
**Regulatory trajectory:** The FDA has been tightening peptide compounding regulations broadly. The legal landscape for compoundable peptides in 2026 is meaningfully different from what it was in 2020. Whether sermorelin's Category 1 status remains stable, or whether future FDA action affects it, is genuinely uncertain. Anyone building a long-term treatment protocol around compounded sermorelin should have a contingency plan.
**Combination products:** Many clinics prescribe sermorelin in combination with ipamorelin or other peptides. The legal status of a combination product isn't simply the sum of its parts — combination preparations have their own regulatory considerations under compounding law, and the evidence base for specific combinations is thinner than for either peptide alone.
---
## FAQ
### Is Sermorelin legal in the US?
Yes — with important conditions. Sermorelin is legal in the US when obtained through a valid prescription from a licensed provider and dispensed by a licensed 503A or 503B compounding pharmacy. Buying it without a prescription, from an unregistered compounder, or from an overseas supplier without a legal importation pathway is not legal.
### Can my doctor prescribe Sermorelin?
Any licensed physician, nurse practitioner, or physician assistant with prescribing authority in your state can prescribe compounded sermorelin. The prescription needs to be based on a legitimate clinical evaluation — not just a questionnaire. Most responsible providers will order baseline IGF-1 levels and document a clinical rationale before prescribing.
### Is it legal to buy Sermorelin online?
Only if the online process involves a licensed prescriber who conducts a legitimate medical evaluation, and the sermorelin is dispensed by a licensed compounding pharmacy. Telehealth platforms that include a real prescriber-patient relationship and use licensed pharmacies are operating legally. Websites that sell sermorelin without requiring a prescription are not.
### What happens if I'm caught with Sermorelin without a prescription?
Possession of a prescription drug without a valid prescription is a violation of federal law and most state laws. Practical enforcement consequences vary — personal-use quantities typically draw less aggressive prosecution than distribution-scale quantities — but the legal exposure is real. More practically, product seized at customs or by law enforcement may not be returned, and you have no recourse if an unregulated product causes harm.
### Is Sermorelin a controlled substance?
No. Sermorelin is not scheduled under the Controlled Substances Act. It's a prescription drug, but it doesn't carry the additional restrictions (DEA registration for prescribers, triplicate prescriptions, quantity limits) that apply to Schedule II–V substances. This distinguishes it from growth hormone itself, which has specific legal restrictions under the Anabolic Steroid Control Act in certain misuse contexts.
### Can compounding pharmacies make Sermorelin?
Yes. Sermorelin is classified as a Category 1 bulk drug substance, which means licensed 503A and 503B compounding pharmacies can legally prepare it. The pharmacy must be licensed in the relevant state, must meet USP sterility standards, and must dispense it pursuant to a valid prescription (for 503A) or to licensed practitioners and healthcare facilities (for 503B).
### Is "research use only" Sermorelin legal for human use?
No. The RUO designation is intended for laboratory research applications, not human administration. Selling sermorelin labeled "research use only" to consumers who intend to inject it is misbranding under the Federal Food, Drug, and Cosmetic Act. The FDA looks at intended use, not labels — and "research use only" is not a legal shield for human-use sales.
### Has anyone been prosecuted for Sermorelin?
The FDA has taken enforcement action against companies marketing unapproved peptide products, including GHRH-class compounds. Consult FDA.gov for current enforcement activity. Criminal prosecution in the peptide space has generally focused on large-scale illegal distributors rather than individual patients, but the legal framework for prosecution exists and has been used.
### How do I find a clinic that's prescribing Sermorelin legally?
Start with MyPeptideMatch's [clinic finder](/clinics). Look for clinics that require lab work before prescribing, use named licensed compounding pharmacies, have licensed medical providers (not just "wellness coaches"), and can explain their prescribing rationale clearly. Our [Sermorelin peptide profile](/peptides/sermorelin) has more detail on what a legitimate treatment protocol looks like.
### How does Sermorelin compare legally to other GHRH analogs?
Sermorelin has a stronger regulatory foundation than most GHRH analogs because of its historical FDA approval and Category 1 compounding status. [Tesamorelin](/peptides/tesamorelin) has an active FDA approval for a specific indication (HIV-associated lipodystrophy), giving it the strongest standing. [CJC-1295](/peptides/cjc-1295) has a more contested compounding history. [Ipamorelin](/peptides/ipamorelin) is also Category 1 but works through a different mechanism. If regulatory standing matters to you — and it should — sermorelin and tesamorelin are the most defensible choices in the GHRH/GHS category.
---
## References
1. Drug Enforcement Administration, Diversion Control Division. "Sermorelin (Geref) — Drug Information." FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.gov.
2. U.S. Food and Drug Administration. "Geref (sermorelin acetate) — Discontinued Drug Product." FDA Orange Book. FDA.gov. Accessed March 2026.
3. U.S. Food and Drug Administration. "Bulk Drug Substances Under Evaluation for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Category 1." FDA.gov. Accessed March 2026.
4. U.S. Food and Drug Administration. "Compounding Laws and Policies: 503A and 503B Facilities." FDA.gov. Accessed March 2026.
5. Walker RF. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" *Clinical Interventions in Aging*. 2006;1(4):307–308. PMID: 18046908.
6. U.S. Food and Drug Administration. "MedWatch: The FDA Safety Information and Adverse Event Reporting Program." FDA.gov. Accessed March 2026.
7. U.S. Food and Drug Administration. "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use." FDA.gov; see also FDA guidance on "research use only" labeling under 21 CFR Part 809. Accessed March 2026.
8. U.S. Food and Drug Administration. "Personal Importation Policy." FDA.gov. Accessed March 2026.
9. Radley DC, Finkelstein SN, Stafford RS. "Off-label prescribing among office-based physicians." *Archives of Internal Medicine*. 2006;166(9):1021–1026. PMID: 16682577.
---
*Legal status last verified: March 2026. Regulatory status of compounded peptides can change with new FDA guidance, Federal Register rulemaking, or enforcement policy shifts. Verify current status with your provider and pharmacy before starting treatment.*
*This content is for informational purposes only and does not constitute medical or legal advice. Consult a licensed healthcare provider before starting any treatment, and consult a licensed attorney for legal advice specific to your situation.*
MyPeptideMatch
